DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) Kits ELISA

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. De plus, nous expédions DNMT3A Anticorps (297) et DNMT3A Protéines (7) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
DNMT3A 1788 Q9Y6K1
Anti-Souris DNMT3A DNMT3A 13435 O88508
DNMT3A 444984 Q1LZ53
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top DNMT3A Kits ELISA sur anticorps-enligne.fr

Showing 2 out of 12 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Fournisseur Livraison Prix Détails
Humain 0.061 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests Connectez-vous pour afficher 13 to 16 Days
$736.84
Détails
Rat 0.094 ng/mL 0.156-10 ng/mL Typical standard curve 96 Tests Connectez-vous pour afficher 12 to 14 Days
$638.00
Détails

Plus Kits ELISA pour DNMT3A partenaires d'interaction

Pig (Porcine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) interaction partners

  1. Data show that the expression levels of the 5 epigenetic modifying genes Dnmt1, Dnmt3a, Hdac1, Kdm3a and Uhrf1 were higher in group pig in highland (TH) than in group Yorkshire in highland (YH).

Cow (Bovine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) interaction partners

  1. The effect of p53 expression on the development of cloned embryos, and its interaction with HDAC1 and DNMT3A are reported.

  2. The expression levels of DNMT3a and DNMT3b were associated with several beef quality traits.

Horse (Equine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) interaction partners

  1. Among 18 genotypes analyzed, we were unable to record any significant differences in 5-methyl-2'-deoxycytidine levels, which suggested that age-related changes in global DNA methylation content are rather a function of time, and not a genetic component.

Human DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) interaction partners

  1. Multiple evidences suggested that PRMT5 repressed transcription of tumor suppressor IRX1 via recruitment of DNMT3A on promoter.

  2. Most had constantly high DNMT3A(mut) transcript levels.

  3. Together findings presented here recognize an inherent role of MTA1 as a modifier of DNMT3a and IGFBP3 expression, and consequently, the role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression.

  4. we developed a modular dCas9-SunTag (dC9Sun-D3A) system that can recruit multiple DNMT3A catalytic domains to a target site for editing DNA methylation. dC9Sun-D3A is tunable, specific, and exhibits much higher induction of DNA methylation at target sites than the dC9-D3A direct fusion protein.

  5. Results indicate that DNMT3A mutations alone do not affect the clinical outcomes of AML patients undergoing allogeneic HSCT, but when accompanied by FLT3-ITD mutations, the OS was significantly reduced (5-year OS 0% for DNMT3A R882mut/FLT3-ITDpos patients vs. 62% DNMT3A R882wt/FLT3-ITDneg, p=0.025) and the relapse rate increased.

  6. Findings suggested that tumor overexpression of DNMT1 and DNMT3A is associated with tumor aggressive behavior and high-methylation status in pituitary adenomas. Data support a possible role of DNMT1 and DNMT3A in TSG promoter methylation leading to pituitary adenoma invasion.

  7. Genetic variation in DNMT3A gene is not associated with gastric cancer.

  8. concluded that miR-876-5p suppressed hepatocellular carcinoma progression by targeting DNMT3A

  9. These findings indicated a novel mechanism by which EID3, a p300 acetyltransferase inhibitor, could directly affect DNMT3A, this enzyme possesses dual methylation and demethylation abilities.

  10. DNMT3A R882 mutation plays an important role in CN-AML patients' prognosis and clinical outcomes in the presence and absence of NPM1 and FLT3 mutations.

  11. a feedback loop between miR-145 and DNMT3A is a potent signature for the Warburg effect in ovarian cancer, promising a potential target for improved anticancer treatment.

  12. In univariable analysis, patients carrying mutations in DNMT3A, U2AF1, and EZH2 had worse overall and relapse-free survival.

  13. Elastic Network Models, information theory, Protein Structure Network, and sequence evolution analysis were used to investigate intrinsic dynamics and allosteric properties of DNMT3A resolved in autoinhibitory and active states. The conformational transition between 2 states shows global motions. The dimer interface has a major role in defining the quaternary structure dynamics and establishing interdomain communication.

  14. HIF1A-AS2 exerted the oncogenic functions in CRC through regulating miR-129-5p/DNMT3A axis.

  15. we found that DNMT3A was responsible for the down-regulation of miR-105 in gastric cancer cells

  16. Taken together, these data demonstrate that adipose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.

  17. Low frequency of DNMT3A mutations in pediatric T-ALL is in striking contrast to adult T-ALL and renders the necessity for the search of other candidate prognostic markers. Combined Sanger sequencing-HRM approach offers a cost-effective option for genotyping DNMT3A coding sequence, with potential clinical application in other hematological malignancies.

  18. 2.65-angstrom crystal structure of the DNMT3A-DNMT3L-DNA complex in which two DNMT3A monomers simultaneously attack two cytosine-phosphate-guanine (CpG) dinucleotides, with the target sites separated by 14 base pairs within the same DNA duplex; mechanistic basis for DNMT3A-mediated DNA methylation and establishment of its aetiological link to human disease

  19. based on the investigation of previously reported variants in patients with Tatton-Brown-Rahman syndrome , we found overlap in the spectrum of DNMT3A variants observed in this disorder and somatic variants in hematological malignancies

  20. The emodininduced downregulation of UHRF1 led to an increase in the level of DNA methyltransferase 3A.

Mouse (Murine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) interaction partners

  1. Dnmt3a appears to regulate satellite cell differentiation via DNA methylation. This mechanism may play a role in the decreased regeneration capacity during atrophy such as in aged sarcopenia.

  2. DNMT3A and TET1 regulate the epigenome and gene expression at specific targets via their functional interplay.

  3. individual pain vulnerability may be inherent mostly in the emotional/affective component of chronic pain and remain consistent in different aspects of negative emotion, in which adaptive changes in the function of DNA methyltransferase 3a for DNA methylation in central amygdala may play an important role.

  4. Taken together, these data demonstrate that adipose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.

  5. The aim of the present study is to investigate spatial and temporal expression levels and subcellular localizations of the DNMT1, DNMT3A, and DNMT3B proteins in the mouse germinal vesicle (GV) and metaphase II (MII) oocytes, and early embryos from 1-cell to blastocyst stages.

  6. our Dnmt3a R878H mice have shown that leukemic cells have altered gene expression and epigenetic regulatory patterns contributing to the growth/survival advantage over WT mice.The present study found that the DNMT3A mutation contributed to hypomethylation in the gene body region of mTOR in Dnmt3aR878H/WT mice.

  7. Knockdown of DNMT3A or DNMT1 protected neurons against mutant Htt-induced toxicity, together demonstrating a requirement for DNMTs in mutant Htt-triggered neuronal death and suggesting a neurodegenerative mechanism based on DNA methylation-mediated transcriptional repression.

  8. Data demonstrate that DNMT3A and DNA methylation are key modulators of mast cell responsiveness to acute and chronic stimulation.

  9. These data suggest that DNMT3a is required for nerve injury-induced and MBD1-mediated epigenetic silencing of the MOR and KOR in the injured DRG. DNMT3a inhibition may serve as a promising adjuvant therapy for opioid use in neuropathic pain management.

  10. Data show that conditional deletion of Dnmt3a and simultaneous "knock in" of Flt3ITD/+, cooperate to drive leukemia development at a faster rate than Dnmt3a loss alone.

  11. Deletion of DNMT3a in postnatal forebrain neurons does no alter affective behavior.

  12. Altogether, the authors demonstrate that Dnmt3a and Dnmt3b protect the epidermis from tumorigenesis and that squamous carcinomas are sensitive to inhibition of PPAR-gamma.

  13. Upon lysolecithin injection in the spinal cord of transgenic mice, study detected defective oligodendrocyte progenitor cells differentiation and inefficient remyelination in the DNA methyltransferase 3a null and DNA methyltransferase 1/DNA methyltransferase 3a null mice.

  14. This is attributed in part to ineffective repression of Tcf1 expression in knockout T cells, as DNMT3a localizes to the Tcf7 promoter and catalyzes its de novo methylation in early effector WT CD8(+) T cells. These data identify DNMT3a as a crucial regulator of CD8(+) early effector cell differentiation and effector versus memory fate decisions.

  15. Compared the activity of individual DNMT3A isoforms in embryonic stem and neuronal progenitor cells and report that these isoforms differ in their genomic binding and DNA methylation activity at regulatory sites. We identify that the longer isoform DNMT3A1 preferentially localizes to the methylated shores of bivalent CpG island promoters in a tissue-specific manner.

  16. Study shows that in the mouse brain during early life, the DNA methyltransferase DNMT3A preferentially binds transiently to intergenic regions and across transcribed regions of lowly expressed genes and that this binding primarily determines the pattern of DNA methylation at CA sequences in the adult brain.

  17. conditional inactivation of Dnmt3a in mouse hematopoietic cells leads to an accumulation of immature progenitors in the thymus, which are less apoptotic. These data demonstrate that Dnmt3a is required for normal T-cell development, and acts as a T-ALL tumor suppressor

  18. These data demonstrate that haploinsufficiency for Dnmt3a alters hematopoiesis and predisposes mice (and probably humans) to myeloid malignancies by a mechanism that is not yet clear.

  19. Loss of DNMT3A expression is associated with development of malignancy.

  20. confirm the transformation potential of DNMT3A(R882H) Tet2(-/-) progenitors and represent the first cooperative model in mice involving Tet2 inactivation driving lymphoid malignancies

DNMT3A profil antigène

Antigen Summary

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase that is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally regulated. Alternative splicing results in multiple transcript variants encoding different isoforms.

Gene names and symbols associated with DNMT3A

  • DNA methyltransferase 3 alpha (DNMT3A) anticorps
  • DNA methyltransferase 3A (Dnmt3a) anticorps
  • DNA methyltransferase 3 alpha (Dnmt3a) anticorps
  • DNA methyltransferase 3 alpha (dnmt3a) anticorps
  • DNA (cytosine-5-)-methyltransferase 3 alpha b (dnmt3ab) anticorps
  • DNMT3A anticorps
  • dnmt3a1 anticorps
  • DNMT3A2 anticorps
  • dnmt6 anticorps
  • M.HsaIIIA anticorps
  • MmuIIIA anticorps

Protein level used designations for DNMT3A

DNA (cytosine-5)-methyltransferase 3A , DNA cytosine methyltransferase 3 alpha , DNA (cytosine-5-)-methyltransferase 3 alpha , DNA MTase HsaIIIA , DNA cytosine methyltransferase 3A2 , DNA methyltransferase 3A , DNA methyl transferase alpha , DNA-methyltransferase 3a , DNA MTase MmuIIIA , DNA methyltransferase MmuIIIA , LOW QUALITY PROTEIN: DNA (cytosine-5)-methyltransferase 3A , DNA (cytosine-5-)-methyltransferase 6

GENE ID SPECIES
100037301 Sus scrofa
359716 Bos taurus
739139 Pan troglodytes
694822 Macaca mulatta
100055881 Equus caballus
482996 Canis lupus familiaris
1788 Homo sapiens
421991 Gallus gallus
100030681 Monodelphis domestica
100344715 Oryctolagus cuniculus
100500776 Ovis aries
100510798 Felis catus
100594618 Nomascus leucogenys
13435 Mus musculus
444984 Rattus norvegicus
100529107 Anolis carolinensis
100721625 Cavia porcellus
553189 Danio rerio
Fournisseurs de qualité sélectionnés pour DNMT3A (DNMT3A) Kits ELISA
Avez-vous cherché autre chose?